Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting

• New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company’s AI-powered platform –
• SAFEbody® precision masking technology integrated across antibody-based modalities in POWERbody® candidates, designed to further enhance efficacy with secured safety –
• Data show safe, powerful and durable immunotherapy for solid tumors can be achieved through combination of the fundamental mechanisms and pathways across the cancer immunity cycle –

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced publication of four abstracts featuring preclinical data from its expanding pipeline in advance of the AACR Annual Meeting 2022 in New Orleans, Louisiana from April 8-13, 2022. The full abstracts are available on the AACR meeting website.

At AACR, presentations will include preclinical results showing the potential best-in-class profiles for three differentiated preclinical product candidates in IND-enabling studies: ADG138, ADG206 and ADG153. The fourth presentation introduces a new capability for the company’s proprietary bispecific T-cell engagers (TCEs) with CD28.

Details for the poster presentations include:

• Title: ADG138, A Novel HER2×CD3 POWERbody™ Integrating Bispecific TCE with Precision Masking to Control Cytokine Release Syndrome and On-Target Off-Tumor Toxicity for Single Agent and Combination Therapies in HER2-Expressing Solid Tumors

  Date: Tuesday April 12, 2022
  Poster Session: 9:00 a.m. – 12:30 p.m. ET
  Onsite Location: Exhibit Halls D-H, Poster Section 37
  Abstract Number: 2869

• Title: ADG206, an anti-CD137 agonistic POWERbody^TM with tailor-made efficacy and safety profiles by strong crosslinking and tumor selective activation for single agent and combinational cancer immunotherapy

  Date: Tuesday, April 12, 2022
  Poster Session: 9:00 a.m. – 12:30 p.m. ET
  Onsite Location: Exhibit Halls D-H, Poster Section 37
  Abstract Number: 2868

• Title: Tumor-targeted CD28 bispecific POWERbody^TM for safe and synergistic T cell-mediated immunotherapy

  Date: Tuesday, April 12, 2022
  Poster Session: 9:00 a.m. – 12:30 p.m. ET
  Onsite Location: Exhibit Halls D-H, Poster Section 38
  Abstract Number: 2888

• Title: ADG153-G1 SAFEbody, a differentiated masked anti-CD47 antibody of IgG1 subclass, demonstrates in vivo anti-tumor activity consistent with enhanced ADCC/ADCP effects and significantly reduced RBC-related and antigen sink liabilities

  Date: Wednesday, April 13, 2022
  Poster Session: 9:00 a.m. – 12:30 p.m. ET
  Onsite Location: Exhibit Halls D-H, Poster Section 39
  Abstract Number: 4257

“These presentations highlight the promise of our AI-driven technology platform to build a deep, broad, and differentiated pipeline of transformative antibody therapeutics,” said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. “Our ‘three-body’ technologies are well suited to discover and engineer antibody-based modalities against clinically important targets such as HER2, TROP2, B7H3, CD137, CD47 and CD28, overcoming challenges of prior platform technologies, validated by clinical data from our ongoing clinical programs, and endorsed by our strategic partnerships with global pharmaceutical and biopharmaceutical companies.”

Dr. Luo continued, “We are designing safe and effective antibody candidates across the cancer immunity cycle, including our POWERbody approach, which integrates the SAFEbody technology with multiple antibody-based modalities. These include ADG138, a new HER2xCD3 bispecific TCE for solid tumors, and ADG206, an Fc engineered anti-CD137 therapy, both designed for enhanced safety and efficacy. Additionally, we are establishing a new paradigm for CD28 TCEs by putting all the pieces together to ensure ultimate safety and mitigate known risks of this target – a unique, highly conserved epitope, our precision masking technology and a tumor antigen targeted TCE for local activation. With these novel therapeutic approaches, we aim to push the boundaries of what is possible with TCEs – to achieve safe, potent and durable responses for solid tumors.”

Source: Adagene